HK Stock Market Move | CANSINOBIO (06185) continues to rise by over 10% DTcP-Hib-MCV4 combination vaccine receives approval for clinical trials.

CANSINOBIO (06185) rose more than 10% again, with the stock rising nearly 9% yesterday. As of the time of writing, it has risen by 10.31%, reaching HK$41.2, with a turnover of HK$147 million. On the news front, CANSINOBIO recently announced that its adsorbed non-cellular pentavalent (component) white broken (DTcP) b-type flu Haemophilus influenzae type b (Hib)-ACYW135 group meningococcal conjugate (MCV4) combination vaccine (DTcPHib-MCV4 combination vaccine) has been approved by the Chinese National Medical Products Administration for conducting relevant clinical trials. The company pointed out that its domestic first meningococcal quadrivalent conjugate vaccine product, Menhacin, which is also a component of the DTcP-Hib-MCV4 combination vaccine, has obtained a drug registration certificate and been commercialized. The infant DTcP is in Phase III clinical trials, while the Hib vaccine is in Phase I clinical trials. FIRST SHANGHAI previously mentioned that CANSINOBIO's meningococcal vaccine product revenue has achieved rapid growth, reaching 516 million yuan in the first three quarters of last year, a year-on-year increase of 39.07%. Menhacin will remain the only MCV4 product in the country in the short term, which is beneficial for further consolidating its position in the Chinese market. The expansion of the age group from 4-6 years is also actively being promoted and is expected to be approved this year. Once approved, it will achieve full coverage of the national immunization plan age group and further promote sales growth. At the same time, Menhacin's overseas market development is steadily progressing, with smooth progress in the Middle East, Southeast Asia, and other regions, expected to contribute a small amount of revenue starting this year.